Monitoring CAR-T cell therapy production using the LUNA-FX7™

Chimeric antigen receptor (CAR) T cell therapy is a 'living' drug established from a patient's own isolated and engineered T cells. To ensure the safety, quality, and efficacy of the final CAR-T cell product, cell health and viability must be evaluated and monitored throughout the process of development and bioprocessing workflows. Discover how the LUNA-FX7™ from Logos Biosystems can be used to monitor and evaluate cell health at critical stages in the CAR-T process: Collection of the primary source material, post-leukapheresis, isolation / activation, expansion, and production.